Casting a Wide Net: HIV Drug Resistance Monitoring in Pre-Exposure Prophylaxis Seroconverters in the Global Evaluation of Microbicide Sensitivity Project.
Journal
Global health, science and practice
ISSN: 2169-575X
Titre abrégé: Glob Health Sci Pract
Pays: United States
ID NLM: 101624414
Informations de publication
Date de publication:
28 04 2022
28 04 2022
Historique:
received:
18
10
2021
accepted:
08
03
2022
entrez:
29
4
2022
pubmed:
30
4
2022
medline:
4
5
2022
Statut:
epublish
Résumé
Evidence of HIV drug resistance (HIVDR) in individuals using oral pre-exposure prophylaxis (PrEP) who acquire HIV is limited to clinical trials and case studies. More data are needed to understand the risk of HIVDR with oral PrEP during PrEP rollout. Mechanisms to collect these data vary, and are dependent on cost, scale of PrEP distribution, and in-country infrastructure for the identification, collection, and testing of samples from PrEP seroconverters. The Global Evaluation of Microbicide Sensitivity (GEMS) project, in collaboration with country stakeholders, initiated HIVDR monitoring among new HIV seroconverters with prior PrEP use in Eswatini, Kenya, South Africa, and Zimbabwe. Standalone protocols were developed to assess HIVDR among a national sample of PrEP users. In addition, HIVDR testing was incorporated into existing demonstration projects for key populations. Countries are supportive of conducting a time-limited evaluation of HIVDR during the early stages of PrEP rollout. As PrEP rollout expands, the need for long-term HIVDR monitoring with PrEP will need to be balanced with maintaining national HIV drug resistance surveillance for pretreatment and acquired drug resistance. Laboratory capacity is a common obstacle to setting up a monitoring system. Establishing HIV resistance monitoring within PrEP programs is feasible. Approaches to drug resistance monitoring may evolve as the PrEP programs mature and expand. The methods and implementation support offered by GEMS assisted countries in developing methods to monitor for drug resistance that best fit their PrEP program needs and resources.
Sections du résumé
BACKGROUND
Evidence of HIV drug resistance (HIVDR) in individuals using oral pre-exposure prophylaxis (PrEP) who acquire HIV is limited to clinical trials and case studies. More data are needed to understand the risk of HIVDR with oral PrEP during PrEP rollout. Mechanisms to collect these data vary, and are dependent on cost, scale of PrEP distribution, and in-country infrastructure for the identification, collection, and testing of samples from PrEP seroconverters.
METHODS
The Global Evaluation of Microbicide Sensitivity (GEMS) project, in collaboration with country stakeholders, initiated HIVDR monitoring among new HIV seroconverters with prior PrEP use in Eswatini, Kenya, South Africa, and Zimbabwe. Standalone protocols were developed to assess HIVDR among a national sample of PrEP users. In addition, HIVDR testing was incorporated into existing demonstration projects for key populations.
LESSONS LEARNED
Countries are supportive of conducting a time-limited evaluation of HIVDR during the early stages of PrEP rollout. As PrEP rollout expands, the need for long-term HIVDR monitoring with PrEP will need to be balanced with maintaining national HIV drug resistance surveillance for pretreatment and acquired drug resistance. Laboratory capacity is a common obstacle to setting up a monitoring system.
CONCLUSIONS
Establishing HIV resistance monitoring within PrEP programs is feasible. Approaches to drug resistance monitoring may evolve as the PrEP programs mature and expand. The methods and implementation support offered by GEMS assisted countries in developing methods to monitor for drug resistance that best fit their PrEP program needs and resources.
Identifiants
pubmed: 35487541
pii: GHSP-D-21-00122
doi: 10.9745/GHSP-D-21-00122
pmc: PMC9053149
pii:
doi:
Substances chimiques
Anti-HIV Agents
0
Anti-Infective Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : PEPFAR
Pays : United States
Informations de copyright
© Levy et al.
Références
J Int AIDS Soc. 2021 Nov;24(11):e25833
pubmed: 34762770
Lancet HIV. 2018 Nov 29;:
pubmed: 30503324
HIV Med. 2021 Feb;22(2):75-82
pubmed: 33140556
Clin Infect Dis. 2021 Jun 1;72(11):2025-2028
pubmed: 32686825
N Engl J Med. 2017 Feb 2;376(5):501-502
pubmed: 28146652
Clin Infect Dis. 2018 Aug 31;67(6):962-964
pubmed: 29961859
Clin Infect Dis. 2020 Jul 27;71(3):583-585
pubmed: 31509603
AIDS. 2017 Sep 10;31(14):2007-2016
pubmed: 28692542
Lancet. 2016 Jan 2;387(10013):53-60
pubmed: 26364263
Int J Infect Dis. 2020 May;94:41-43
pubmed: 32173577
PLoS One. 2018 Jan 19;13(1):e0191294
pubmed: 29351338
Drugs. 2019 Aug;79(12):1263-1276
pubmed: 31309457
Lancet Infect Dis. 2014 Sep;14(9):820-9
pubmed: 25065857
J Acquir Immune Defic Syndr. 2017 Jul 1;75(3):271-279
pubmed: 28328548
Drugs. 2019 Apr;79(6):609-619
pubmed: 30963509
AIDS. 2016 Jul 31;30(12):1973-83
pubmed: 27149090
Sex Health. 2018 Nov;15(6):578-586
pubmed: 30408432
AIDS. 2018 Jun 1;32(9):F1-F4
pubmed: 29683856
J Int AIDS Soc. 2019 Dec;22(12):e25419
pubmed: 31850686
AIDS Rev. 2010 Oct-Dec;12(4):195-208
pubmed: 21179184
Curr Opin HIV AIDS. 2016 Jan;11(1):49-55
pubmed: 26633640
J Acquir Immune Defic Syndr. 2017 Dec 1;76(4):e104-e106
pubmed: 29076941
AIDS. 2018 Oct 23;32(16):2353-2361
pubmed: 30096070
JAMA. 2018 Mar 27;319(12):1261-1268
pubmed: 29584848
AIDS Behav. 2018 Nov;22(11):3718-3725
pubmed: 30006791
J Infect Dis. 2021 Apr 23;223(8):1345-1355
pubmed: 31851759
Lancet HIV. 2019 Feb;6(2):e137-e140
pubmed: 30660592
Curr Opin HIV AIDS. 2017 Mar;12(2):182-189
pubmed: 28059958
Can J Public Health. 2018 Jan 22;108(5-6):e643-e645
pubmed: 29356678